Our Docket No: 05247P004D Patent

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)		
Eric A. Holwitt	)	Examiner:	Not Yet Assigned
Application No: Not Yet Assigned	)	Art Unit:	Not Yet Assigned
Filed: Not Yet Assigned	)		
For: Compositions and Methods of Use of	)		
8-Nitroguanine	) )		



## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form PTO-1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form PTO-1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

Docket No.: 05247P004D

Express Mail No.: EL886507006US

The In	formation Disclosure Statement is being filed: (a) within three months of the filing date of the patent application, (b) within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application, or (c) before the mailing date of a first Office Action on the merits.
	after (a), (b), or (c) above, but before the mailing date of a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, and includes:
	the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below).
	the fee of \$180 set forth in 37 C.F.R. § 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, and includes the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below), a Petition requesting consideration of the Information Disclosure Statement (see "Petition" below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see "Fees" below).
Copie	S Of The References Copies of certain references listed on the enclosed Form PTO-1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 C.F.R. § 1.98(a)(3).
	A copy of the foreign search report is enclosed herewith.
	All references listed on the enclosed Form PTO-1449 were previously identified in the parent application of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 C.F.R. § 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 U.S.C. § 120 in which copies of the references were previously furnished are set out below:

U.S. APPI	Status (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1. 09/850,646	May 7, 2001		X	
2. 60/203,062	May 9, 2000		X	
3.				

Docket No.: 05247P004D

	r Applications  The Examiner's atte	ention is directed to the	following U.S.	patent applic	ration(s):
	U.S. APPLIC	CATIONS	S	tatus (check o	one)
τ	J.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.					
2.	74.77				
3.					
Fees		ne applicant(s). 0.00 under 37 C.F.R. § \$130.00 set forth in 37			
Meth	Charge Deposit Acc	ees in the amount of \$ 180.0 ount No. 02-2666 in the aclosed for that purpose	amount of \$.	(A duplicate	copy of this
Auth	orization To Charge	Additional Fees			
$\boxtimes$		s are owed in connection 02-2666. (A duplicate			
Instr	uctions As To Overpa	nyment			
$\square$	Credit Account No. Refund	02-2666.			
		Respectfully submitte	d,		
Date:	November し, 2001	Richard A. Nakashima Reg. 42,023		& ZAFMAN	ILLP

12400 Wilshire Blvd., 7th Floor Los Angeles, CA 90025-1026 (303) 740-1980 (303) 740-6962 (facsimile)

Docket No.: 05247P004D

Express Mail No.: EL886507006US

PTO/SB/08A (08-00) d for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Su	bstitute for for	m 1449	VPTO	Com		
(modified)				Applicati n Number	Not Yet Assigned	51
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Filing Date	Concurrently Herewith	803		
		First Named Inventor	Eric A. Holwitt	- 50 - 00 - 00 - 00 - 00 - 00 - 00 - 00		
		Group Art Unit	Not yet assigned	007		
Ob 4	Sheet 2 of 4		Examiner Name	Not yet assigned	JC JC	
Sneet			Attorney Docket Number	05247P004D		

	T -	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	C1	BURNEY et al., "The chemistry of DNA damage from nitric oxide and peroxynitrite", Mutation Res., 424:37-49, 1999	
	C2	BURNEY, S. et al., "DNA damage in deoxynucleosides and oligonucleotides treated with peroxynitrite", Chem. Res., Toxicol., 12:520, 1999	
	C3	BYUN, J. et al., "8-Nitro-2'deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by the myeloperoxidase-hydrogen peroxidenitrate system of activated human phagocytes", Biochemistry, 38:2590-2600, 1999	
	C4	CHWANG, T. Ling et al., "Synthesis of nucleoside nitrates", J. Carbohydrates	
_	C5	DIPLOCK, et al., "Functional food science and defence against reactive oxidative species", Brit. J. Nutrition 80 (Supp. 1):S77-S112, 1998	
	C6	DOUKI, Thierry et al., "An adduct between peroxynitrite and 2'-deoxyguanosine: 4,5-dihydro-5-hydroxy-4-(nitrosooxy)-2'deoxyguanosine", Chem. Res. Toxicol., 9:3-7, 1996	
	C7	FUKUYAMA, et al., "Clinical evidence of peroxynitrite formation in chronic renal failure patients with septic shock", Free Radical Biol. & Med. 22:771-774, 1997	
		HOLWITT, Joel, "The effect of peroxynitrite on DNA synthesis of 8-nitroguanine and a physical chemical study", Presented to the Intel International Science and Engineering Fair, May 5, 1999	
	C9	HOLWITT, Gregory, "The synthesis and detection of 8-nitroganine in DNA", Presented to the Intel International Science and Engineering Fair, May 10, 2000	
		HAUNG, Guang-Fu and TORRENCE, Paul F., "Nitration of pyrimidine bases and nucleotides by nitronium tetrafluoroborate, synthesis of 5-nitro-2'-deoxyuridine", Journal of Organic Chemistry, 42 (24) 3821:3824, 1977	
		HUGHES, "Relationships between nitric oxide, nitroxyl ion, nitrosonium cation and peroxynitrite." Biochim. Biophys. Acta 1411:263-272, 1999	

		<del></del>
Examiner	Doto	
Ditailini	Date	
Signatura		
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document wIPO Standard St.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00) d for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if known		
(modified)			001105	Application Number	Not Y t Assigned	
INFORMATION DISCLOSURE		Filing Dat	Concurr ntly H rewith			
317	STATEMENT BY APPLICANT			First Nam d Inventor	Eric A. Holwitt	
(use as	s many shee	ets as r	necessary)	Group Art Unit	Not yet assigned	
Sheet 3 of 4		Examiner Name	Not yet assigned			
		Attorney Docket Number	05247P004D			

	r	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, scrial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C12	HURST AND LYMAR, "Toxicity of peroxynitrite and related reactive nitrogen species towards Escherichia coli", Chem. Res. Toxicol. 10:802-810, 1997	
	C13	JAYASENA, S.D., "Aptamers: An Engineering Class of Molecules That Rival Antibodies in Diagnostics", Clin. Chem. 45:1628-1650, 1999	
	C14	LIN, Weiei et al., "Study on DNA strand breaks induced by sodium nitroprusside, a nitric oxide donor, in vivo and in vitro", Mut. Research, 466:187-195, 2000	
	C15	LOVE, "Oxidative stress in neurological disease", Brain Pathol. 9:119-131, 1999	
		OIKAWA, Shinji and KAWANISHI, Shosuke, "Site specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening", FEBS Letters 453:365-368, 1999	
	C17	ROUTLEDGE, Michael N., "Mutations induced by reactive nitrogen oxide species in the supF forward mutation assay", Mutation Research 450, 95-105, 450	
		SCHWEMMER, M., et al. "How urine analysis reflects oxidative stress-nitrotyrosine as a potential marker", Clin. Chim. Acta 297:207-216, 2000	
	i	SPENCER, J.P.E. et al., "Base modification and Strand Breakage in Isolated Calf Thymus DNA and in DNA from Human Skin Epidermal Keratinocytes Exposed to Peroxynitrite or 3-Morpholinosyndnonimine," Chemical Research in Toxicology, 9 (1996), p1 152-1158	
		TRETYAKOVA et al., "Peroxynitrite-induced DNA damage in the supF gene: correlation with the mutational spectrum", Mutation Res. 447:287-303, 2000	
	i	TUO et al., "Importance of guanine nitration and hydroxylation in DNA in vitro and in vivo", Free Radical Biol. & Med. 29:147-155, 2000	
		YERMILOV, V., et al., "Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination. "FEBS Letters, 376:207-210, 1995a	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substi	tute for (use as	Form 1449A/	PTO (Meried) ecessary) Page 1 of 4		Attorney Docket No. 05247P004D	Application Numl Not Yet A	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Named Inventor:	Eric A. Holwitt		
(use as many sheets as necessary)  Sheet 1 of 4		Filing Date:		Filing Date:	Concurrently Herewith		
			-	U.S. PATEN	NT DOCUMENTS		
xam. nitial*	Cite No. <sup>1</sup>	U.S. Pate Number Code <sup>2</sup>	ent Document Kind (If known)	Na	ame of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures
	A1	5,484,707		Goldblur	n et al.	01/16/1996	Appear
	A2	6,093,723		Miao et a	1.	07/25/2000	o <b>=</b>
	A3	6,096,556		Heinecke	, Jay W.	08/01/2000	<u> </u>
	A4	6,113,324		Huber, E		09/05/2000	88
	A5	6,113,898		Anderson	n, Darrell R. et al.	09/05/2000	-8
	A6	6,200,978		Maw et a	1.	03/13/2001	100
							n =

				FOR	REIGN PATENT DOCUMEN	TS		
Exam. Initial*	Cite No.1	Office <sup>3</sup> Code <sup>5</sup>	eign Patent D Number <sup>4</sup>	Nocument  Kind  (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te

Examiner	Date Considered	
Signature	Jule Goldsteller	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard S.3). <sup>4</sup>For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Appeled for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			VPTO	Complete if known	
(modified)				Application Number	Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	Concurrently Herewith
			LICANI	First Named Inventor	Eric A. Holwitt
(use as many sheets as necessary)			necessary)	Group Art Unit	Not yet assigned
Sheet	4	of	4	Examiner Name	Not yet assigned
				Attorney Docket Number	05247P004D

Examiner	Cita	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Initials	Cite No. <sup>1</sup>	item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	$T^2$
	C23	YERMILOV, V., "Formation of 8-nitroguanine by the reaction of Guanine with	
	C23	peroxynitrite in vitro", Carcinogenesis 16:2045-2050, 1995B YERMILOV, V., et al., "Effects of carbon dioxide/bicarbonate on induction of DNA	
	C24	single-strand breaks and formation of 8-nitroguanine, 8-oxoguanine and base – propenal mediated by peroxyn in rite," FEBS Letters, 399:67-70, 1996	
	02.	proposal mediated by peroxyn in rite, TEBS Letters, 399.07-70, 1996	-
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
	T = 1		
	1		

Examiner	Date	
	Date	
Signature	Considered	
2.8.1	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number.

2 See attached Kinds of U.S. Patent Documents.

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible.

8 Applicant is to place a check mark here if English language Translation is attached.